CYBN:CC News and Press, CYBIN INC. From 05/11/22

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chie...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons , the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman says LSD and MDMA helped him alleviate symptoms rel...

- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days - - Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - Kernel , a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYB...

The U.S. Army is being sued for violating the Constitution as well as its own regulations and veterans’ rights by failing to give soldiers with drug and alcohol use disorders honorable discharges, which would have qualified them for federal benefits. Army Secretary Christine Wormu...

Data from the National Institute on Drug Abuse shows that millions of individuals in America have already battled or will battle addiction to drugs, with 85% of them relapsing within one year of treatment. A recently launched program is hoping to lower this number significantly. The progr...

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Precl...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentati...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that an abstract highlighting preclinical data for its deuterated psilocybin an...

Depression is a mood disorder that causes an individual to experience feelings of sadness that persist for longer than a fortnight, which impacts their ability to carry out daily activities. A recently conducted study has found that individuals who use antidepressants to manage their depre...